PRGS&Tech Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
25
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$13.2K
PRGS&Tech General Information
Description
Developer of medicines designed to treat rare diseases. The company's medicines include looking into the causes of rare gammopathies, developing medicines that target such causes, and finding a cure for neurodegenerative diseases, including aging and dementia, through treatments for gammopathies, enabling patients to receive treatments for gammopathies.
Contact Information
Website
prgst.comCorporate Office
- 9th Floor, Sejeong Tower
- 252, Geumjeong-ro
- Busan, Geumjeong 46274
- South Korea
Corporate Office
- 9th Floor, Sejeong Tower
- 252, Geumjeong-ro
- Busan, Geumjeong 46274
- South Korea
PRGS&Tech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 15-Jun-2026 | $13.2K | Completed | Clinical Trials - Phase 2 | ||
| 5. Merger/Acquisition | 17-Mar-2026 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | Completed | Clinical Trials - Phase 2 | ||||
| 3. Early Stage VC (Series B) | 01-Sep-2021 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 01-May-2019 | Completed | Startup | |||
| 1. Seed Round | 30-Jun-2018 | Completed | Startup |
PRGS&Tech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PRGS&Tech Patents
PRGS&Tech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024417139-A1 | Method for preparing novel compound | Pending | 05-Jan-2024 | ||
| EP-4806888-A1 | Method for preparing novel compound | Pending | 05-Jan-2024 | ||
| WO-2025146850-A1 | Method for preparing novel compound | Inactive | 05-Jan-2024 | ||
| AU-2023463541-A1 | Composition for preventing or treating alzheimer's disease, containing novel compound | Pending | 31-Aug-2023 | ||
| EP-4830706-A1 | Composition for preventing or treating alzheimer's disease, containing novel compound | Pending | 31-Aug-2023 | A61P25/28 |
PRGS&Tech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PRGS&Tech Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BNK Venture Capital | Venture Capital | Minority | ||
| Hana Ventures | Corporate Venture Capital | Minority | ||
| Jeonbuk Technology Holdings | Venture Capital | Minority | ||
| KNET Investment Partners | Venture Capital | Minority | ||
| Korea Development Bank | VC-Backed Company | Minority |
PRGS&Tech FAQs
-
When was PRGS&Tech founded?
PRGS&Tech was founded in 2017.
-
Where is PRGS&Tech headquartered?
PRGS&Tech is headquartered in Busan, South Korea.
-
What is the size of PRGS&Tech?
PRGS&Tech has 25 total employees.
-
What industry is PRGS&Tech in?
PRGS&Tech’s primary industry is Drug Discovery.
-
Is PRGS&Tech a private or public company?
PRGS&Tech is a Private company.
-
What is PRGS&Tech’s current revenue?
The current revenue for PRGS&Tech is .
-
How much funding has PRGS&Tech raised over time?
PRGS&Tech has raised $13.2K.
-
Who are PRGS&Tech’s investors?
BNK Venture Capital, Hana Ventures, Jeonbuk Technology Holdings, KNET Investment Partners, and Korea Development Bank are 5 of 9 investors who have invested in PRGS&Tech.
-
When was PRGS&Tech acquired?
PRGS&Tech was acquired on 15-Jun-2026.
-
Who acquired PRGS&Tech?
PRGS&Tech was acquired by Sentynl Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
